BridgeMD
Prospective study to evaluate the efficacy of letermovir prophylaxis for the prevention of CMV infection in lung transplant recipients compared to a retrospective cohort treated with standard valganciclovir prophylaxis for 12 months (LETERCOR Study).
EU CTIS ID: 2023-504384-16-00
What this study is testing
Evaluate the efficacy of letermovir prophylaxis for 12 months in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who were prescribed with a 12-month prophylaxis with valganciclovir to prevent CMV disease.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 18 years and older
- Lung transplant patients (D+/R-) pre-transplant
- Have an undetectable PCR-CMV within 96 hours prior to the start of letermovir prophylaxis (prospective cohort)
- Patients who have given their written informed consent (prospective cohort)
- Patients prescribed (intention to treat) with valganciclovir prophylaxis for 12 months (retrospective cohort)
- Patients transplanted between 18/05/2020 and 18/11/2022 (retrospective cohort)
You likely can't join if
- HIV-infected patients
- Multivisceral transplant patients
- Patients who cannot comply with the study protocol (prospective cohort)
- Receiving an antiviral prophylaxis other than ganciclovir or valganciclovir prior to letermovir prophylaxis (prospective cohort)
- Patients with simultaneous renal and hepatic insufficiency (prospective cohort)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.